无创通气与经鼻高流量氧疗对AECOPD急性高碳酸血症性呼吸衰竭患者神经呼吸驱动效率的影响:随机交叉研究
本研究为前瞻性随机交叉试验,纳入10例AECOPD合并失代偿性高碳酸血症性急性呼吸衰竭患者,每例分别接受30分钟NIV和HFNO治疗,通过多对食管电极导管测量神经呼吸驱动(NRD)。结果显示,NIV较HFNO显著改善神经-通气耦联(治疗差异1.73 L/%,95%CI 0.95至2.51 L/%,p=0.001)。HFNO和NIV均较常规氧疗(COT)提高NRD效率。NIV较COT和HFNO更显著改善吸气负荷、呼吸肌收缩和呼吸做功,表现为Peso、Pdi、PTPdi/次和PTPdi/min降低。HFNO较COT也显示出生理获益,但神经-机械效率和PTPdi/次除外。
要点
- NIV较HFNO显著改善神经-通气耦联,治疗差异1.73 L/%(95%CI 0.95至2.51 L/%,p=0.001)。
- NIV较COT和HFNO更显著降低Peso、Pdi、PTPdi/次和PTPdi/min,改善吸气负荷、呼吸肌收缩和呼吸做功。
- HFNO和NIV均较COT提高NRD效率。
- HFNO较COT显示出生理获益,但神经-机械效率和PTPdi/次除外。
- 作者认为HFNO虽不如NIV有效,但仍可提供可测量的生理获益,可能作为资源有限或不耐受NIV患者的替代选择,可能更适合呼吸衰竭较轻的患者。
适用人群与场景
- AECOPD合并失代偿性高碳酸血症性急性呼吸衰竭患者。
处置流程与药物剂量
- 每例患者分别接受30分钟NIV和HFNO治疗。
研究设计与关键结果
- 前瞻性随机交叉试验,纳入10例AECOPD合并失代偿性高碳酸血症性急性呼吸衰竭患者,每例接受30分钟NIV和HFNO治疗,通过多对食管电极导管测量NRD。
- NIV较HFNO显著改善神经-通气耦联,治疗差异1.73 L/%(95%CI 0.95至2.51 L/%,p=0.001)。
- HFNO和NIV均较COT提高NRD效率。
- NIV较COT和HFNO更显著改善吸气负荷、呼吸肌收缩和呼吸做功,表现为Peso、Pdi、PTPdi/次和PTPdi/min降低。
- HFNO较COT显示出生理获益,但神经-机械效率和PTPdi/次除外。
证据类型、等级与局限
- 证据类型:前瞻性随机交叉试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在AECOPD合并失代偿性高碳酸血症性急性呼吸衰竭患者中,NIV显著提高NRD效率并降低呼吸做功和相关呼吸力学指标。
- 作者认为,HFNO虽不如NIV有效,但仍可提供可测量的生理获益,可能作为资源有限或不耐受NIV患者的替代选择,可能更适合呼吸衰竭较轻的患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Non-invasive ventilation (NIV) is recommended as the first-line treatment for patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) complicated by decompensated hypercapnic acute respiratory failure (ARF). High-flow nasal cannula oxygen therapy (HFNO), given its superior tolerance and patient adherence, has emerged as a promising alternative non-invasive respiratory support modality applicable across a wider range of clinical scenarios. This study aimed to investigate the neurophysiological effects of NIV and HFNO in AECOPD patients with hypercapnic ARF.
METHODS: A prospective, randomised, crossover trial involving 10 AECOPD patients with decompensated hypercapnic ARF was conducted. Each patient underwent 30 min of treatment with both NIV and HFNO, with the neural respiratory drive (NRD) measured via a multi-pair oesophageal electrode catheter.
RESULTS: NIV significantly improved neuro-ventilatory coupling compared with HFNO (treatment difference: 1.73 L/%, 95% CI: 0.95 to 2.51 L/%, p = 0.001). Both HFNO and NIV enhanced NRD efficiency relative to conventional oxygen therapy (COT). Furthermore, NIV led to more pronounced improvements in inspiratory workload, respiratory muscle contraction, and work of breathing-evidenced by reductions in Peso, Pdi, PTPdi/breath, and PTPdi/min-compared with both COT and HFNO. HFNO also demonstrated physiological benefits over COT, with the unexpected exception of the neuro-mechanical efficiency and PTPdi/breath.
CONCLUSION: In AECOPD patients with decompensated hypercapnic ARF, NIV significantly enhances NRD efficiency and reduces respiratory workload and related respiratory mechanics. HFNO, while less effective than NIV, still confers measurable physiological benefits and may serve as a viable alternative in resource-limited settings or those who are intolerant to NIV, potentially more appropriate for patients with less severe respiratory failure.
TRIAL REGISTRATION: ClinicalTrials.gov, NCT04212182. Registered 23 December 2019, https://clinicaltrials.gov/study/NCT04212182.
参考来源
- Guan L, Xu J, He Z, et al. Efficiency of neural respiratory drive changes during non-invasive ventilation and high-flow nasal cannula oxygen therapy in AECOPD patients with acute hypercapnic respiratory failure: A randomised cross-over study. Ann Intensive Care. 2026. PMID: 41788481. doi:10.1016/j.aicoj.2025.100019
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。